Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-HyART: Dose Escalation in Head and Neck Cancer
NCT06087614Phase 2Recruiting
- Sponsor
- Rajiv Gandhi Cancer Institute and Research Centre
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Rajiv Gandhi Cancer Institute and Research Centre. Primary endpoint: Locoregional Control at 24 months. Started Apr 2024; status: recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06087614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087614.